Page 1 | Search Results | Blood | American Society of Hematology

1-12 of 12

Sort by

Sort Order Select

Journal Articles

Markedly Reduced FVIII Recovery Associated with Anti-FVIII Peg Antibodies after BNT162b2 Sars-Cov-2 Vaccination

Carla Valsecchi, Roberta Gualtierotti, Sara Arcudi, Alessandro Ciavarella, Lucia Schiavone, Cristina Novembrino, Simona Maria Siboni, Pier Mannuccio Mannucci, Flora Peyvandi

Blood (2022) 140 (Supplement 1): 11286–11287.

https://doi.org/10.1182/blood-2022-162183

Published: 2022

Journal Articles

Anti-Emicizumab Antibodies Do Not Cross-React with Mim8 in Vitro

Roberta Gualtierotti, Carla Valsecchi, Chiara Suffritti, Eugenia Biguzzi, Sara Arcudi, Lucia Schiavone, Flora Peyvandi

Blood (2021) 138 (Supplement 1): 3193.

https://doi.org/10.1182/blood-2021-151221

Published: 2021

Journal Articles

Which Level of Emicizumab Is Necessary for a Good Hemostasis?

Alessandro Ciavarella, Sara Arcudi, Eugenia Biguzzi, Roberta Gualtierotti, Cristina Novembrino, Simona Siboni, Carla Valsecchi, Flora Peyvandi

Blood (2021) 138 (Supplement 1): 4247.

https://doi.org/10.1182/blood-2021-150627

Published: 2021

Journal Articles

Real-World Experience with Emicizumab Prophylaxis in the Milan Cohort: A Single-Center Experience

Sara Arcudi, Alessandro Ciavarella, Roberta Gualtierotti, Sonia Marino, Marco Boscarino, Simona Siboni, Eugenia Biguzzi, Lucia Schiavone, Cristina Novembrino, Carla Valsecchi, Flora Peyvandi

Blood (2021) 138 (Supplement 1): 1038.

https://doi.org/10.1182/blood-2021-151483

Published: 2021

Journal Articles

Prediction of Anti-FVIII Inhibitor Persistence By Anti-FVIII IgG Subclasses in Patients with Severe Hemophilia — A in the Sippet Cohort Study

Flora Peyvandi, MD PhD, Paolo Bucciarelli, MD, Carla Valsecchi, BSc, Marco Boscarino, Roberta Palla, PhD, Elena Santagostino, Amal El-Beshlawy, Mohsen Saleh Elalfy, MD, Vijay M. Ramanan, MBBS,MDDM, Peyman Eshghi, MD, Suresh Hanagavadi, MD, Mehran Karimi, MD, Cecil Ross, MD, Mamta V Manglani, MD, Guy Young, Tulika Seth, MDMBBS,FAAP, Shashikant Apte, MD FRCPA, Dinesh M Nayak, MD, Maria Elisa Mancuso, Johnny Mahlangu, Bonanad Santiago, MD, Monica H Cerqueira, MD PhD, Nadia P Ewing, MD, Christoph Male, MD, Tarek Owaidah, MDFRCPA, Veronica Soto Arellano, MD, Suvankar Majumdar, MBCHB, Mindy Simpson, MD, Mathew Thomas, MD, Ezio Zanon, Marilyn J Manco-Johnson, MD, Monica Martinez, MD, Maria Gabriella Mazzucconi, MD, Daniela Neme, MD, Rogelio Alejandro Paredes-Aguilera, MD, Alessandra N L Prezotti, MD MSc, Klaus Schmitt, MD, Bulent Zulfikar, Prof, Pier Mannuccio Mannucci, MD, Frits Richard Rosendaal, MD

Blood (2018) 132 (Supplement 1): 384.

https://doi.org/10.1182/blood-2018-99-114599

Published: 2018

Journal Articles

Nonneutralizing antibodies against factor VIII and risk of inhibitor development in severe hemophilia A

Antonino Cannavò, Carla Valsecchi, Isabella Garagiola, Roberta Palla, Pier Mannuccio Mannucci, Frits R. Rosendaal, Flora Peyvandi

Blood (2017) 129 (10): 1245–1250.

https://doi.org/10.1182/blood-2016-06-720086

Published: 2017

Includes: Supplemental data

Journal Articles

The Role of ADAMTS13-Specific Circulating Immune Complexes in Prediction of Recurrence of Acquired Thrombotic Thrombocytopenic Purpura

Barbara Ferrari, Carla Valsecchi, Silvia Pontiggia, Ilaria Mancini, Luca Andrea Lotta, Danijela Mikovic, Giovanna Meloni, Flora Peyvandi

Blood (2014) 124 (21): 1467.

https://doi.org/10.1182/blood.V124.21.1467.1467

Published: 2014

Journal Articles

ADAMTS13 Content of Plasma-Derived Factor VIII-Von Willebrand Factor Concentrates

Flora Peyvandi, Pier Mannuccio Mannucci, MD, Carla Valsecchi, Silvia Pontiggia, Jonathan Bernstein, MS, MD, Stefano Guazzini, PhD, Anastassios Retzios, PhD

Blood (2012) 120 (21): 3383.

https://doi.org/10.1182/blood.V120.21.3383.3383

Published: 2012

Journal Articles

ADAMTS13 Activity and Autoantibodies Subclasses as Recurrency Risk Predictors In Acquired Thrombotic Thrombocytopenic Purpura

Giuseppe Bettoni, Luca A Lotta, Dario Consonni, Dino FA Motti, Roberta Palla, Carla Valsecchi, Gloria Casoli, Andrea Rovati, Michele Pizzuti, Flora Peyvandi, MD, PhD

Blood (2010) 116 (21): 2532.

https://doi.org/10.1182/blood.V116.21.2532.2532

Published: 2010

Journal Articles

Risk Factors for Recurrence of Thrombotic Thrombocytopenic Purpura.

Flora Peyvandi, MD, PhD, Silvia Lavoretano, Roberta Palla, Hendrik B. Feys, Tullia Battaglioli, MD, PhD, Carla Valsecchi, Maria T. Canciani, Fabrizio Fabris, MD, Pier M. Mannucci, MD

Blood (2006) 108 (11): 1060.

https://doi.org/10.1182/blood.V108.11.1060.1060

Published: 2006

Journal Articles

The First Deletion Mutation in the TSP1-6 Repeat Domain of ADAMTS13 Leads to a Secretion Defect.

Flora Peyvandi, MD, PhD, Silvia Lavoretano, PhD, Roberta Palla, PhD, Isabella Garagiola, PhD, Carla Valsecchi, PhD, Rossana Lombardi, PhD, Maria T. Canciani, PhD, Pier M. Mannucci, MD

Blood (2005) 106 (11): 3960.

https://doi.org/10.1182/blood.V106.11.3960.3960

Published: 2005

Journal Articles

In Vitro Expression Studies of Two Mutations on the Metalloprotease and First Cub Domains of the ADAMTS-13 Gene Leading to Severe ADAMTS-13 Deficiency and Chronic Recurrent TTP.

Flora Peyvandi, MD, PhD, Silvia Lavoretano, PhD, Raimondo De Cristofaro, MD, Carla Valsecchi, PhD, Giuliana Merati, PhD, Antonella Lattuada, PhD, Pier M. Mannucci, MD

Blood (2004) 104 (11): 514.

https://doi.org/10.1182/blood.V104.11.514.514

Published: 2004

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Markedly Reduced FVIII Recovery Associated with Anti-FVIII Peg Antibodies after BNT162b2 Sars-Cov-2 Vaccination

Anti-Emicizumab Antibodies Do Not Cross-React with Mim8 in Vitro

Which Level of Emicizumab Is Necessary for a Good Hemostasis?

Real-World Experience with Emicizumab Prophylaxis in the Milan Cohort: A Single-Center Experience

Prediction of Anti-FVIII Inhibitor Persistence By Anti-FVIII IgG Subclasses in Patients with Severe Hemophilia — A in the Sippet Cohort Study

Nonneutralizing antibodies against factor VIII and risk of inhibitor development in severe hemophilia A

The Role of ADAMTS13-Specific Circulating Immune Complexes in Prediction of Recurrence of Acquired Thrombotic Thrombocytopenic Purpura

ADAMTS13 Content of Plasma-Derived Factor VIII-Von Willebrand Factor Concentrates

ADAMTS13 Activity and Autoantibodies Subclasses as Recurrency Risk Predictors In Acquired Thrombotic Thrombocytopenic Purpura

Risk Factors for Recurrence of Thrombotic Thrombocytopenic Purpura.

The First Deletion Mutation in the TSP1-6 Repeat Domain of ADAMTS13 Leads to a Secretion Defect.

In Vitro Expression Studies of Two Mutations on the Metalloprotease and First Cub Domains of the ADAMTS-13 Gene Leading to Severe ADAMTS-13 Deficiency and Chronic Recurrent TTP.

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only